Literature DB >> 23953757

NSE level in combined neuroendocrine and adenocarcinoma EGFR mutated lung cancer resistant to EGFR-TKI.

Francesco Facchinetti1, Marcello Tiseo, Letizia Gnetti, Enrico Maria Silini, Andrea Ardizzoni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23953757     DOI： 10.1016/j.lungcan.2013.07.018

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  3 in total

1.  Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.

Authors:  Jin-Yan Liang; Fan Tong; Fei-Fei Gu; Yang-Yang Liu; Yu-Lan Zeng; Xiao-Hua Hong; Kai Zhang; Li Liu
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

2.  Secondary biopsy of non-oncogenic-driven lung cancer may reveal a clinically sensible histologic change. A brief report of two paradigmatic cases.

Authors:  Maria C Mengoli; Giulia Orsi; Filippo Lococo; Giulia Grizzi; Fausto Barbieri; Federica Bertolini; Giulio Rossi; Silvia Novello
Journal:  Thorac Cancer       Date:  2017-04-06       Impact factor: 3.500

3.  Genetic alterations and protein expression in combined small cell lung cancers and small cell lung cancers arising from lung adenocarcinomas after therapy with tyrosine kinase inhibitors.

Authors:  Xiaohua Shi; Huanli Duan; Xuguang Liu; Liangrui Zhou; Zhiyong Liang
Journal:  Oncotarget       Date:  2016-06-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.